Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Cash from Investing Activities (2016 - 2025)

Utah Medical Products (UTMD) has 16 years of Cash from Investing Activities data on record, last reported at -$27000.0 in Q3 2025.

  • For Q3 2025, Cash from Investing Activities rose 69.66% year-over-year to -$27000.0; the TTM value through Sep 2025 reached -$271000.0, up 6.23%, while the annual FY2024 figure was -$208000.0, 67.45% up from the prior year.
  • Cash from Investing Activities reached -$27000.0 in Q3 2025 per UTMD's latest filing, up from -$51000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $5000.0 in Q1 2024 and bottomed at -$321000.0 in Q3 2022.
  • Average Cash from Investing Activities over 5 years is -$130473.7, with a median of -$90000.0 recorded in 2023.
  • Peak YoY movement for Cash from Investing Activities: skyrocketed 111.63% in 2024, then crashed 3780.0% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at -$253000.0 in 2021, then soared by 84.98% to -$38000.0 in 2022, then tumbled by 136.84% to -$90000.0 in 2023, then surged by 90.0% to -$9000.0 in 2024, then plummeted by 200.0% to -$27000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$27000.0 in Q3 2025, -$51000.0 in Q2 2025, and -$184000.0 in Q1 2025.